SCHEMBL23052005

SCHEMBL23052005

CCCCCCC(=O)NCCCCCCCC(=O)O

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.81
CASP2 P42575 1/20 0.71
KDM4E B2RXH2 1/20 0.69
PLA2G2A P14555 1/20 0.69
FAAH O00519 1/20 0.68
NAAA Q02083 1/20 0.67
GPR84 Q9NQS5 7/20 0.65
PPARG P37231 6/20 0.65
PPARD Q03181 6/20 0.65
PPARA Q07869 6/20 0.65
HDAC11 Q96DB2 5/20 0.65
TSHR P16473 4/20 0.65
ALDH1A1 P00352 2/20 0.65
TLR2 O60603 2/20 0.65
TDP1 Q9NUW8 2/20 0.65
FABP4 P15090 2/20 0.65
PTPN1 P18031 2/20 0.65
SLC22A6 Q4U2R8 1/20 0.65
SLC22A8 Q8TCC7 1/20 0.65
MEN1 O00255 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1131391 1.00 EPHX2 (0.81) EPHX2CASP2KDM4EPLA2G2AFAAH
SCHEMBL15649579 1.00 EPHX2 (0.81) EPHX2CASP2KDM4EPLA2G2AFAAH
SCHEMBL9266547 1.00 EPHX2 (0.81) EPHX2CASP2KDM4EPLA2G2AFAAH
SCHEMBL8044633 1.00 EPHX2 (0.81) EPHX2CASP2KDM4EPLA2G2AFAAH
SCHEMBL15259281 1.00 EPHX2 (0.81) EPHX2CASP2KDM4EPLA2G2AFAAH
SCHEMBL8041499 1.00 EPHX2 (0.81) EPHX2CASP2KDM4EPLA2G2AFAAH
SCHEMBL16013677 1.00 EPHX2 (0.81) EPHX2CASP2KDM4EPLA2G2AFAAH
SCHEMBL22072061 1.00 EPHX2 (0.81) EPHX2CASP2KDM4EPLA2G2AFAAH
SCHEMBL22684645 1.00 EPHX2 (0.81) EPHX2CASP2KDM4EPLA2G2AFAAH
SCHEMBL2150959 1.00 EPHX2 (0.81) EPHX2CASP2KDM4EPLA2G2AFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230165932-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME LLC 2023-06-01 US disclosed
US-20230165932-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME LLC 2023-06-01 US disclosed
US-20210069288-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME LLC 2021-03-11 US disclosed
WO-2021041770-A1 PCSK9 ANTAGONIST COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2021-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210069288-A1 PCSK9 ANTAGONIST COMPOUNDS PCSK9, PCSK7, PCSK6 EPHX2 2213/4885CASP2 2186/4885KDM4E 3212/4885
US-20230165932-A1 PCSK9 ANTAGONIST COMPOUNDS PCSK9, PCSK7, PCSK6 EPHX2 2213/4885CASP2 2186/4885KDM4E 3212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.